Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

MLA

Ella Willenbacher, et al. “Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-Inferiority, Phase 3 Trial and Its Extension Study.” The Lancet Haematology, vol. 7, Mar. 2020, pp. e196–208. EBSCOhost, https://doi.org/10.1016/s2352-3026(19)30236-4.

APA

Ella Willenbacher, Zita Borbényi, Steffen Koschmieder, Robert Kralovics, Mario Cazzola, Uwe Platzbecker, Emanuil Gheorghita, Pencho Georgiev, Heinz Gisslinger, Mathieu Puyade, Malgorzata Calbecka, Jerome Rey, Kurt Krejcy, Jiri Mayer, Krzysztof Warzocha, Emilie Cayssials-Caylus, Veronika Buxhofer-Ausch, János Jakucs, Anna Vallova, … Viktor Rossiev. (2020). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. The Lancet Haematology, 7, e196–e208. https://doi.org/10.1016/s2352-3026(19)30236-4

Chicago

Ella Willenbacher, Zita Borbényi, Steffen Koschmieder, Robert Kralovics, Mario Cazzola, Uwe Platzbecker, Emanuil Gheorghita, et al. 2020. “Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-Inferiority, Phase 3 Trial and Its Extension Study.” The Lancet Haematology 7 (March): e196–208. doi:10.1016/s2352-3026(19)30236-4.